Hormonal health
Building femtech that works in the exam room, not just the App Store

By Dr Somi Javaid, OB/GYN, surgeon and founder of HerMD
A patient once came to me with a folder full of app screenshots; five different trackers, each with its own opinion about her ovulation, hormone levels, and supposed “menopause stage.”
She was overwhelmed, confused, and frustrated. And she’s not alone.
In the last decade, femtech has exploded, period trackers, ovulation calculators, vaginal health apps, wearable menopause sensors.
The space is buzzing with innovation, but many of these tools fall short where it matters most: the exam room.
As an OB/GYN who’s led over 115,000 patient encounters and founded a women’s health company, I’ve seen firsthand the gap between what the tech world builds and what women actually need.
Here’s the hard truth: many femtech products are built for the app store, not the clinical workflow. They’re beautifully branded and investor-ready, but they often fail to integrate with medical realities.
Hormone health, for example, is complex, deeply individual, constantly evolving, and often mismanaged due to outdated care models and a lack of clinician guidance.
Yet, many apps offer templated advice, oversimplified dashboards, or outdated data that can leave patients more confused than empowered.
I’ve seen patients arrive at my office with data overload and decision paralysis. But when I ask about their symptoms, history, and labs, it tells a very different story.
That disconnect isn’t just frustrating, it can be dangerous. Women deserve tools that enhance care, not complicate it.
Part of the problem is who gets invited to build.
Too often, startups create in a vacuum, without OB/GYNs, menopause specialists, or sexual health experts at the table.
The result? Aesthetically beautiful products that don’t scale clinically; or worse, ignore the nuanced realities of women’s health altogether.
And here’s what often gets missed from a bird’s-eye view: solutions don’t get adopted in a 15-minute appointment.
It’s not because providers are unwilling, it’s because no one teaches how to take innovation and integrate it into the messy, high-pressure rhythm of everyday care.
If tech doesn’t reduce friction, it won’t last.
Providers don’t need gift wrapped solutions for problems that do not exist, they need the real problems addressed and solved. That involves MD leadership and adoption.
Take menopause.
It’s not a one-size-fits-all experience. It’s a physiological transition, yes, but it also intersects with sleep, mood, metabolism, sexual wellness, and identity.
An app that only tracks hot flashes is missing the point, and missing the patient.
And while AI and digital diagnostics are promising, without clinical oversight and validation, they risk reinforcing the same biases and gaps women have long endured in healthcare.
If we want to build femtech that truly transforms outcomes, we have to start in the exam room.
That means asking: What do patients actually bring to their providers? What slows down care? What enhances trust?
What helps us move from symptom management to real healing? How do we bridge the educational gap for providers and patients?
When technology is co-designed with clinicians, it can reduce admin burden, enhance decision-making, and make time for what matters most… listening.
At HerMD, we’ve worked to build systems that reflect this.
We integrate digital platforms with real-time patient input, personalised care plans, and evidence-based protocols.
Our tech is designed not to replace the clinician, but to empower the patient; to give her language, agency, and support.
That only works because it’s grounded in the realities of what patients and providers experience every day.
This also means thinking globally.
In many parts of the world, women still face significant barriers to specialist care.
Femtech can help bridge that gap, but only if it’s designed with cultural context, medical integrity, and inclusive research in mind.
Femtech doesn’t need more features. It needs more feedback loops between innovation and lived experience.
It needs fewer pitch decks and more peer-reviewed pilots. And it needs founders and funders to prioritize function over flash.
If we get this right, we won’t just digitise women’s health.
We’ll revolutionise it, with tech that earns its place in the exam room and in women’s lives.
Insight
PCOS renamed after decade-long campaign to end ‘cyst’ misconception
Hormonal health
Tampons could track MS nerve damage, study suggests

Menstrual fluid collected from tampons could one day provide a simple, non-invasive way to measure a biomarker of nerve damage and potentially track disease activity in neurological conditions such as multiple sclerosis (MS), new research suggests.
Because neurofilament light chain, or NfL, has emerged as a promising biomarker of MS, detecting it in menstrual fluid raises the possibility of monitoring disease activity through the natural monthly cycle of menstruation.
Researchers at Nextgen Jane, in collaboration with Siemens Healthineers, found that NfL, a protein released when nerve cells are damaged, can be reliably detected in tampon-collected menstrual samples.
“Finding that NfL tracks with estrogen levels in menstrual fluid, independent of how much blood is in the sample, tells us there is real biology here, not just contamination,” said Ridhi Tariyal, chief executive and co-founder of Nextgen Jane.
“That changes what this specimen means for neurology.”
In MS, the immune system mistakenly attacks healthy parts of the brain and spinal cord, causing inflammation and damage that can lead to symptoms such as fatigue, numbness, muscle weakness, and problems with balance or vision.
Confirming a diagnosis of MS usually requires a combination of physical and neurological examinations, MRI scans to check for brain and spinal cord damage, and lab tests.
These can include detecting certain proteins in cerebrospinal fluid, the fluid that surrounds the brain and spinal cord, which may indicate inflammation in the brain or spinal cord.
After diagnosis, patients are usually monitored through clinical assessments and routine MRI scans, which help doctors detect changes in disease activity and determine whether treatments are working.
However, MRI assessments can be costly and are usually done once or twice a year, which can prevent doctors from spotting early changes and making timely treatment adjustments.
Because of these challenges, researchers have long sought cost-effective, more accessible biomarkers that could help detect MS earlier, monitor disease activity over time, and evaluate treatment response.
One of the most promising candidates is NfL, a protein found in nerve cell fibres that is released into the bloodstream and cerebrospinal fluid when nerve cells are injured.
To explore whether menstrual fluid could serve as a source for detecting this biomarker and, more broadly, as a non-invasive specimen for monitoring neurological, hormonal and inflammatory signals, researchers analysed 99 tampon-collected menstrual fluid samples from 91 participants.
They used Siemens Healthineers’ highly sensitive NfL assay on its automated testing platform. The team also measured hormonal and inflammatory molecules.
NfL was detected in 98 of the 99 menstrual fluid samples analysed, suggesting the biomarker can be reliably measured in tampon-collected samples.
The researchers also found that NfL levels were associated with estradiol levels, a form of the hormone oestrogen, and that this relationship remained significant even after adjusting for differences in blood content between samples.
By comparison, levels of inflammatory markers were more strongly linked to blood content itself.
According to the researchers, this suggests NfL detection was not merely the result of blood contamination, but may reflect biologically meaningful changes that could potentially be tracked over time through routine menstrual sampling.
Building on these findings, Nextgen Jane is now planning prospective studies to investigate whether menstrual NfL and other neurological proteins can be used to track disease activity over time in conditions such as MS.
“The menstrual cycle provides a built-in longitudinal framework: the same individual, the same biological process, month after month,” said Stephen Gire, chief scientific officer at Nextgen Jane.
“Coupling the NextGen Jane platform with Siemens Healthineers’ highly sensitive NfL assay gives us a path to study neurological biomarker trajectories in a way that has not been possibe before.”
Fertility
Toxins and climate harms having ‘alarming’ effect on fertility, research warns

Simultaneous exposure to toxic chemicals and climate-related heat may be worsening fertility harms across humans and wildlife, research suggests.
The review of scientific literature looks at how endocrine-disrupting chemicals, often found in plastic, together with climate-related effects such as heat stress, are each linked to lower fertility and fecundity, meaning the ability to reproduce, across species including humans, wildlife and invertebrates.
Though the reproductive harms of each issue in isolation are well studied, there is little research on what happens when living organisms are exposed to both.
“Together, the two issues are likely to pose a greater threat to fertility, and the additive effect is “alarming”, said Susanne Brander, a study lead author and courtesy faculty at Oregon State University.
“You’re not just getting exposed to one, but two, stressors at the same time that both may affect your fertility, and in turn the overall impact is going to be a bit worse,” Brander said.
The paper looked at 177 studies.
Shanna Swan, a co-author on the new paper, co-produced a 2017 study that found sperm levels among men in western countries had fallen by more than 50 per cent over four decades. Other research has suggested human fertility has been declining at a similar rate.
The University of Washington’s Institute for Health Metrics and Evaluation has previously said the world was approaching a “low-fertility future”, with more than three quarters of countries below replacement rate by 2050.
The new paper’s authors focused on the effects of endocrine-disrupting chemicals and substances, including microplastics, bisphenol, phthalates and PFAS.
These are thought to cause a range of serious reproductive problems, disrupt hormones and be a potential driver of falling fertility.
Brander said the harms linked to these chemicals are often similar across organisms, from invertebrates to humans.
Phthalates, for example, have been linked to altered sperm shape in invertebrates, spermatogenesis in rodents, meaning sperm production, and reduced sperm counts in humans.
PFAS are also thought to affect sperm quality, and both have been linked to hormone disruption.
The chemicals are widespread in consumer goods, so people are often regularly exposed.
Meanwhile, previous research has shown how rising temperatures, lower oxygen levels and heat stress, among other effects linked to climate change, may also worsen infertility.
Heat stress has been found to affect human hormones, and is linked to spermatogenesis in rodents and bulls.
Research shows temperature also plays a role in sex determination in fish, reptiles and amphibians.
The species has evolved to choose which sex it produces in part based on temperature, and the heating planet can “push it too far in one direction or the other, which overrides that evolutionary benefit”, Brander said.
Similarly, many endocrine disruptors may alter environmental sex determination.
The study set out some of the overlapping effects of chemical exposure and climate change across taxonomic groups, from invertebrates to humans.
In birds, for example, exposure to increased temperature, PFAS, organochlorines and pyrethroids may each individually cause abnormal sperm, increased fledgling mortality, abnormal testes and population decline.
“What happens if they’re exposed to more than one of those stressors at the same time? There has been little exploration of that question.
“Even if there have not been a lot of studies looking at these simultaneously, if you have two different factors that both cause the same adverse effect, then there’s a likelihood that they are going to be additive,” Brander said.
Katie Pelch, a senior scientist with the Natural Resources Defense Council nonprofit, who was not part of the study, said the authors had reviewed high-quality science.
She said she wanted to see more examples of the overlap in impacts, but agreed with the overall premise.
“It is likely [multiple stressors] would have an additive effect, at very least, even if they have different mechanisms of harm,” Pelch added.
The solution to the systemic problems would involve tackling climate change and reducing the use of toxic chemicals.
The study cites the global reduction in the use of DDT and PCBs achieved under the Stockholm Convention as an example of an effective measure, but Brander said much more is needed.
“There is enough evidence in both areas to act to reduce our impact on the planet,” she said.
Entrepreneur3 weeks agoFuture Fertility raises Series A financing to scale AI tools redefining fertility care worldwide
News2 weeks agoWomen’s digital health market set to reach US$5.28 billion in 2026 – report
Fertility4 weeks agoFuture Fertility partners with Japan’s leading IVF provider, Kato Ladies Clinic
Cancer3 weeks agoNew meta-analysis further supports low re-excisions and high placement accuracy with the Magseed marker
Mental health3 weeks agoLifting weights shows mental health and cognitive benefits in older women, study finds
News3 weeks agoResistance training has preventative effects in menopause, study finds
Pregnancy3 weeks agoNIPT or NT scan? Why the 2026 evidence supports doing Both
Hormonal health4 weeks agoRelaunched women’s health strategy aims to tackle ‘medical misogyny’
















1 Comment